

A study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in Roche-sponsored studies

| | | |
|--|---|--|
| Submission date 12/07/2021 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| | | <input type="checkbox"/> Protocol |
| Registration date 06/08/2021 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| Last Edited 05/12/2023 | Condition category Eye Diseases | <input type="checkbox"/> Individual participant data |
| | | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims:

The purpose of this study is to assess long-term safety of faricimab therapy and provide access to continued treatment with faricimab, as applicable, to patients with Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (nAMD), or Retinal Vein Occlusion (RVO).

Faricimab is an experimental drug, which means health authorities have not approved it for the treatment of DME, nAMD, or RVO outside of a clinical study. As of November 2020, more than 3,350 patients have been enrolled in either the completed or ongoing clinical studies of faricimab in patients with DME and nAMD. Of these patients, more than 2,100 patients have received at least one dose of faricimab.

Who can participate?

Patients who were previously enrolled in the mainland of China and completed any of Roche-sponsored faricimab parent trials

What does the study involve?

Participants will be placed in a single treatment group:

Participants will receive faricimab 6 mg injections into the study eye at a variable interval depending on the condition of their eye. Frequency of injections will be determined by the study doctor, usually varying between every 4 weeks and every 16 weeks.

Participants will only be required to attend the clinic according to the study doctor's discretion, but the interval between visits should be no more than 4 months and no less than 21 days.

What are the possible benefits and risks of participating?

Your health may or may not improve in this study, but the information that is learned may help other people who have a similar medical condition in the future.

You may have side effects from the drugs or procedures used in this study. Side effects can be mild to severe and even life threatening, and they can vary from person to person. There may be

a risk in exposing an unborn child to the study drug, and all risks are not known at this time. Women and men must take precautions to avoid exposing an unborn child to the study drug.

Where is the study run from?
Shanghai General Hospital (China)

When is the study starting and how long is it expected to run for?
August 2020 to August 2025

Who is funding the study?
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech Inc (USA)

Contact information

Type(s)

Public

Contact name

Mr Clinical Trials

Contact details

1 DNA Way
South San Francisco
United States of America
94080
+41 616878333
global.trial_information@roche.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

YR42837

Study information

Scientific Title

An open-label, multicenter extension study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in studies sponsored by F. Hoffmann-La Roche Ltd

Study objectives

To investigate the long-term safety and tolerability of faricimab administered in patients previously enrolled in Roche-sponsored studies

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 05/03/2021, Shanghai General Hospital Institutional Review Board (No. 100, Haining Road, Shanghai, 200080, China; +86-21-36123569; Shiyilunli@sina.com), ref: [2021]026

Study design

Non-randomized open-label multicenter standalone extension study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Macular degeneration

Interventions

Participants will be placed in a single treatment group:

Participants will receive faricimab 6 mg injections into the study eye at a variable interval depending on the condition of their eye. Frequency of injections will be determined by the study doctor, usually varying between every 4 weeks and every 16 weeks.

Participants will only be required to attend the clinic according to the study doctor's discretion, but the interval between visits should be no more than 4 months and no less than 21 days.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Faricimab (RO6867461)

Primary outcome(s)

1. Eye condition measured using BCVA, pre-treatment IOP, slit-lamp examination, and Indirect ophthalmoscopy measured at baseline (Day 1) and each visit which is in the range of 21 days to 4 months

2. Effect of drug measured using finger-counting test and IOP (post-study treatment) are measured after each administration. As the study drug administration has no mandatory timepoint and is decided by the clinical judgment of the investigator, these assessments have no specified timepoint

3. Other eye tests, SD-OCT, CFP, and FFA are also measured according to the investigator's discretion, they have no specified timepoint

Key secondary outcome(s)

There are no secondary outcome measures

Completion date

04/08/2025

Eligibility

Key inclusion criteria

1. Previous enrollment in and completion of any faricimab parent study without study or study drug discontinuation.
2. Enrolled in the mainland of China
3. Signed Informed Consent Form
4. Ability and willingness to comply with the study protocol, in the investigator's judgment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Sex

All

Key exclusion criteria

1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 28 days after the final ITV injection of faricimab
2. Women of childbearing potential must have a negative urine pregnancy test result within 28 days prior to initiation of study treatment. If the urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.

Date of first enrolment

19/07/2021

Date of final enrolment

04/04/2025

Locations

Countries of recruitment

China

Study participating centre

Shanghai General Hospital

Shanghai

China

201620

Sponsor information

Organisation

F. Hoffman-la Roche

Funder(s)

Funder type

Industry

Funder Name

Genentech

Alternative Name(s)

Genentech, Inc., Genentech USA, Inc., Genentech USA

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to there being no regulatory requirement to do so.

IPD sharing plan summary

Not expected to be made available

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|---------------|--------------|------------|----------------|-----------------|
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |